MAPT and Alzheimer disease: A key microglial marker, TREM-2, has also been noted as being elevated in AD patient CSF [18, 51] and has recently been linked to slower Aβ deposition [17], reduced cognitive decline [18] and tau-related neurodegeneration [52].